ADMS Adamas Pharmaceuticals Inc

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report 2020 first quarter financial results on Thursday, May 7, 2020, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 5:00 p.m. Eastern Time to discuss the financial results and provide a corporate update.

Investor Conference Call and WebcastThe conference call can be accessed by dialing (844) 215-3280 for participants in the U.S. or Canada and (484) 747-6383 for international callers. All callers must provide the following Conference ID: 3483897. The webcast can be accessed live via the investor section of the Adamas website at ir.adamaspharma.com/events-presentations and will be available for replay until August 7, 2020.

About Adamas Pharmaceuticals, Inc.At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com. 

Contact

Investors: Peter VozzoManaging Director, Westwicke443-213-0505 peter.vozzo@westwicke.com

Media: Sarah MathiesonVice President, Corporate Communications510-450-3528smathieson@adamaspharma.com